Rosuvastatin calcium in acute coronary syndromes

@article{Aggarwal2013RosuvastatinCI,
  title={Rosuvastatin calcium in acute coronary syndromes},
  author={R. Aggarwal and R. Showkathali},
  journal={Expert Opinion on Pharmacotherapy},
  year={2013},
  volume={14},
  pages={1215 - 1227}
}
Introduction: Low-density lipoprotein cholesterol (LDL-C) reduction using 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) has a proven survival benefit in patients presenting with acute coronary syndromes (ACS). Patients presenting with ACS remain at significant risk of subsequent cardiovascular death and non-fatal myocardial infarction despite high compliance with current guideline indicated secondary prevention therapies. There remains, therefore, a need to… Expand
Review on Rosuvastatin
TLDR
In vivo studies in animals, and in vitro studies in polite animal and human cells have shown rosuvastatin to possess a high uptake into, and property for, action within the liver, the organ for sterol lowering. Expand
Rosuvastatin protects against oxidized low-density lipoprotein-induced endothelial cell injury of atherosclerosis in vitro
TLDR
Findings indicated that rosuvastatin could protect HUVECs against ox-LDL-induced injury through its anti-oxidant effect and its ability to upregulate the expression of vascular endotheliocyte-protecting factors. Expand
Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
TLDR
Co-administration of fimasartan and rosuvastatin did not result in clinically relevant changes in the systemic exposure of fimsartan or rosuVastatin after single and multiple administrations, and they were well tolerated. Expand
Neuroprotective Effects of Rosuvastatin in Spinal Cord Ischemia-Reperfusion Injury in Rabbits
TLDR
Rosuvastatin may protect the spinal cord tissue against ischemic damage, by its anti-inflammation and antiapoptotic effect and may be a good candidate for clinical use during surgical procedures on the thoracoabdominal aorta. Expand
The relative bioavailability of 2 prototype fixed‐dose combination formulations for amlodipine and rosuvastatin in healthy white and Chinese subjects
TLDR
The FDC formulations demonstrated similar bioavailability to coadministered commercially available amlodipine and rosuvastatin and all treatments were generally well tolerated. Expand
Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor
Abstract During the process development for multistep synthesis of Rosuvastatin calcium several impurities were obtained along with the final Rosuvastatin calcium. Out of this; synthesis of impurityExpand
The Effect of Exosomes Derived from Bone Marrow Stem Cells in Combination with Rosuvastatin on Functional Recovery and Neuroprotection in Rats After Ischemic Stroke
TLDR
It seems that the use of exosomes and rosuvastatin, as a novel treatment regimen, might promote neurological recovery after the onset of stroke. Expand
FORMULATION AND CHARACTERIZATION OF ROSUVASTATIN CALCIUM NANOPARTICLES
Article history The aim of this study is to formulate and characterize Rosuvastatin loaded Chitosan nanoparticles prepared by ionic-gelation method. Rosuvastatin Calcium has a low bioavailabilityExpand
Quantitative Analysis of Rosuvastatin Calcium in Bulkand Solid Pharmaceutical Dosage Forms Using Greenand Rapid Fourier-Transform Infrared SpectroscopicMethod
A fast, inexpensive and direct quantitative Fourier-Transform Infrared Spectroscopic method was established for rosuvastatin calcium for analysis in bulk and solid pharmaceutical dosage forms.Expand
Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.
Recombinant DNA technology and corresponding innovations in molecular biology, chemistry and medicine have led to novel therapeutic biomacromolecules as lead candidates in the pharmaceutical drugExpand
...
1
2
...

References

SHOWING 1-10 OF 96 REFERENCES
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
  • L. Lopez
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2002
TLDR
Statins are highly effective for improving cardiovascular outcomes in high-risk patients but are frequently underused and closer attention to potential adverse effects will be necessary before any expansion in statin use. Expand
The evolving role of statins in the management of atherosclerosis.
TLDR
Clinical and experimental evidence indicates that the beneficial actions of statins occur rapidly and yield potentially clinically important anti-ischemic effects as early as one month after commencement of therapy. Expand
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
TLDR
Rosuvastatin exerts rapid immunomodulatory effects on the level of T-cell activation in patients with ACS and significantly reduced plasma concentrations of pro-inflammatory cytokines TNF-alpha and IFN-gamma at 72 h. Expand
Rosuvastatin: efficacy, safety and clinical effectiveness.
TLDR
Rosuvastatin has a potent low-density cholesterol lowering action and has potentially favourable effects on high-density lipoprotein (HDL), non-HDL-C, triglycerides and the apolipoprotein B : A1 ratio, and could prove to be the most clinically effective statin. Expand
Early statin initiation and outcomes in patients with acute coronary syndromes.
TLDR
There was no relationship between early initiation of statin therapy and improved outcomes although a subset analysis suggests that outcomes after early statin initiation may vary with cholesterol levels. Expand
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
TLDR
Results from the LUNAR study show that RSV40 more effectively decreased LDL cholesterol, increased HDL cholesterol, and improved other blood lipid parameters than ATV80 in patients with acute coronary syndrome. Expand
Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy
  • R. Rosenson
  • Medicine
  • American journal of cardiovascular drugs : drugs, devices, and other interventions
  • 2001
TLDR
Treatment with HMG-CoA reductase inhibitors improved endothelial dysfunction in patients with hypercholesterolemia and this improvement in endothelial function was not correlated with reduction in total serum cholesterol levels. Expand
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
  • M. Davidson
  • Medicine
  • Expert opinion on investigational drugs
  • 2002
TLDR
Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system and should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals. Expand
Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
TLDR
In patients with mild to moderate hypercholesterolemia, rosuvastatin has been shown to produce large decreases in LDL-C at starting doses, thus reducing the need for subsequent dose titration, and to allow greater percentages of patients to attain lipid goals, compared with available statins. Expand
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
TLDR
Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg ofAtorvaston per day, with a greater incidence of elevated aminotransferase levels. Expand
...
1
2
3
4
5
...